Tarsus Pharmaceuticals (TARS) Competitors $41.50 -0.94 (-2.21%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$41.52 +0.02 (+0.06%) As of 07/25/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. RGC, RVMD, GRFS, TGTX, NUVL, RYTM, CRSP, AXSM, TLX, and LNTHShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Its Competitors Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Nuvalent Rhythm Pharmaceuticals CRISPR Therapeutics Axsome Therapeutics Telix Pharmaceuticals Lantheus Tarsus Pharmaceuticals (NASDAQ:TARS) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk. Which has more risk & volatility, TARS or RGC? Tarsus Pharmaceuticals has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Regencell Bioscience has a beta of 2.29, indicating that its share price is 129% more volatile than the S&P 500. Do insiders and institutionals hold more shares of TARS or RGC? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, TARS or RGC? Regencell Bioscience has lower revenue, but higher earnings than Tarsus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$233.67M7.46-$115.55M-$2.73-15.20Regencell BioscienceN/AN/A-$4.30MN/AN/A Is TARS or RGC more profitable? Regencell Bioscience has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Regencell Bioscience's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-44.91% -39.72% -25.74% Regencell Bioscience N/A N/A N/A Do analysts recommend TARS or RGC? Tarsus Pharmaceuticals presently has a consensus target price of $66.67, suggesting a potential upside of 60.64%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Tarsus Pharmaceuticals is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to TARS or RGC? In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 3 articles in the media. Tarsus Pharmaceuticals' average media sentiment score of 1.26 beat Regencell Bioscience's score of 1.19 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTarsus Pharmaceuticals beats Regencell Bioscience on 8 of the 13 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.74B$3.06B$5.69B$9.50BDividend YieldN/A2.37%4.58%4.01%P/E Ratio-15.2021.1828.1020.05Price / Sales7.46288.62432.4890.19Price / CashN/A42.7636.2258.56Price / Book7.078.378.665.87Net Income-$115.55M-$55.19M$3.25B$258.55M7 Day Performance-4.05%5.88%4.22%3.73%1 Month Performance2.90%17.33%10.51%11.75%1 Year Performance65.93%4.42%34.40%18.03% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals1.5333 of 5 stars$41.50-2.2%$66.67+60.6%+47.0%$1.74B$233.67M-15.2050Positive NewsRGCRegencell Bioscience0.2394 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010Positive NewsRVMDRevolution Medicines4.4972 of 5 stars$38.42+0.3%$68.91+79.4%-16.8%$7.13B$11.58M-9.61250News CoverageGRFSGrifols3.317 of 5 stars$10.00+0.6%$10.30+3.0%+29.8%$6.83B$7.81B8.5523,822Positive NewsUpcoming EarningsTGTXTG Therapeutics3.7099 of 5 stars$37.42-1.3%$43.80+17.0%+84.7%$6.02B$329M157.96290Positive NewsNUVLNuvalent3.203 of 5 stars$82.46-1.1%$119.60+45.0%+1.8%$5.99BN/A-18.7840RYTMRhythm Pharmaceuticals3.128 of 5 stars$88.63-0.6%$91.93+3.7%+74.3%$5.68B$130.13M-31.54140Analyst UpgradeCRSPCRISPR Therapeutics2.5448 of 5 stars$65.33+0.3%$71.75+9.8%+12.5%$5.62B$37.31M-14.45460Analyst ForecastHigh Trading VolumeAXSMAxsome Therapeutics4.744 of 5 stars$109.68-1.8%$172.33+57.1%+17.3%$5.50B$385.69M-19.01380News CoveragePositive NewsAnalyst RevisionTLXTelix PharmaceuticalsN/A$16.50+1.7%$22.33+35.4%N/A$5.49B$516.72M0.00N/ANews CoverageAnalyst RevisionHigh Trading VolumeLNTHLantheus4.7056 of 5 stars$71.56+2.0%$131.20+83.3%-35.4%$4.86B$1.53B20.33700Positive News Related Companies and Tools Related Companies Regencell Bioscience Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Rhythm Pharmaceuticals Alternatives CRISPR Therapeutics Alternatives Axsome Therapeutics Alternatives Telix Pharmaceuticals Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredThe AI Chip Trade is OUT. This is in…Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TARS Stock Alerts